
Robotic-Assisted Gynecological Surgery Market Size, Share, Trends & Global Forecast 2026–2035
The Robotic-Assisted Gynecological Surgery Market is Segmented By Robotic System (Multi-Port Robotic Systems, Single-Port Robotic Systems, Modular Robotic Systems, Specialised Robotic Platforms), By Procedure (Robotic Hysterectomy, Robotic Myomectomy, Robotic Endometriosis Surgery, Robotic Pelvic-Floor Surgery, Robotic Adnexal Surgery, Robotic Gynecologic Oncology, Other Procedures), By Technology (Telerobotics, Single-Port Robotics, Modular Robotics, 3D Visualisation, AI-Assisted Surgery, Force Feedback & Haptics, Fluorescence-Guided Surgery, Surgical Navigation), By Clinical Indication (Uterine Fibroids, Endometriosis, Pelvic Organ Prolapse, Gynecologic Cancers, Abnormal Uterine Bleeding, Adnexal Disorders, Other Conditions), By End User (Hospitals, Academic Medical Centres, Ambulatory Surgical Centres, Specialty Gynecology Clinics, Cancer Centres, Women's Health Centres), and Region
Robotic-Assisted Gynecological Surgery Market Overview and Definition
The Global Robotic-Assisted Gynecological Surgery Market was valued at USD 2.85 Billion in 2025, and is projected to reach USD 11.15 Billion by 2035, growing at a CAGR of 14.6% from 2026 to 2035. The market includes the range of robotic assisted platforms for minimally invasive surgeries for gynaecology requiring high levels of accuracy, dexterity and surgeon control. The factors boosting the market include the increase in demand for less invasive treatment methods, development of haptic technology and 3D imaging, increased use of robots in academic medical centers and hospitals, as well as broader application areas of robotic surgery beyond hysterectomy and myomectomy surgeries. Currently, multiport robots are dominating the market; however, single-port and modular robotic platforms have the highest growth rate. North America has the largest market share because of high investments in health care infrastructure, availability of reimbursement opportunities and technological advancements.
Key Market Trends & Analysis
- The Global Robotic-Assisted Gynecological Surgery Market valued at USD 2.85 billion in 2025 with strong multi-regional growth momentum across developed and emerging markets.
- Market expansion at a compound annual growth rate of 14.6% from 2026 to 2035 reflects sustained adoption of minimally invasive surgical solutions across healthcare systems globally.
- Projected market size of USD 11.15 billion by 2035 represents a near four-fold increase, driven by technological maturation and procedural volume expansion in diverse gynaecological specialties.
- Minimally invasive surgical demand underpins market growth through reduced postoperative pain, shortened recovery periods and decreased complication rates compared to conventional open surgical approaches.
- Multi-port robotic systems currently capture the dominant market position, establishing the reference standard for gynaecological robotic procedures across hospital networks.
- Single-port robotic systems represent the fastest-growing market segment, expanding at approximately 19% annually through improved ergonomics and reduced trocar site trauma during endometrial and adnexal procedures.
- Robotic hysterectomy procedures constitute the largest clinical application, encompassing uterine fibroid management and benign pathology intervention across institutional settings globally.
- North America accounts for approximately 48% of global market share, reinforced by established surgical robotics infrastructure, dense surgeon training capacity and reimbursement certainty from major payers.
- The United States leads all countries within North America with approximately 82% regional market share, reflecting concentrated adoption in teaching hospitals and progressive private surgical centres.
- In January 2026, Johnson & Johnson submitted its Ottava soft-tissue robotic system for FDA de novo authorisation, representing a major competitive intervention challenging established market leadership positions.
- Asia-Pacific markets demonstrate accelerated growth trajectories at approximately 17% CAGR, propelled by rising healthcare investment, increasing prevalence of gynaecological disorders and expanding surgeon training infrastructure in China and India.
- Robotic endometriosis surgery displays robust expansion, growing at approximately 16% annually as surgeon familiarity increases and patient awareness strengthens regarding superior cosmetic and functional outcomes compared to open approaches.
- The United States robotic-assisted gynaecological surgery market reached approximately USD 1.36 billion in 2025 and is forecast to reach USD 5.35 billion by 2035, expanding at approximately 14.8% annually within the North American context.
Robotic-assisted gynaecological surgery market is made up of advanced surgical platforms, special surgical instruments, maintenance and support infrastructures used in minimally invasive surgical operations. Some of the key technologies used in the market are multiport and single port robots, 3D high definition visualization, haptic feedback technology, AI assisted surgical modules, fluorescence-guided imaging and navigation system. Players in the market are robotic platforms manufacturers, surgical instruments suppliers, service providers and health care institutions. The market end users are hospitals, academic centers, ambulatory surgical centers, specialty centers and cancer centers. Applications include hysterectomy, myomectomy, endometriosis therapy, pelvic floor reconstruction, adnexal surgery and gynaecological oncology operations.
Source: Kaiso Research and Consulting
Robotic gynaecology surgery is revolutionizing minimally invasive surgery techniques with higher precision, fewer complications, and faster patient recovery times. Healthcare providers use robots to improve their competitiveness and retain talented surgeons as well as introduce new treatment techniques. Robotic training has been focusing on robotic console training, instrument handling, and troubleshooting issues related to technology. Higher volumes of procedures, efficiency gains in manufacturing, and competition can lead to cost reductions in terms of purchase and maintenance of the robotic devices. The integration of artificial intelligence allows automation of standard tasks that leave time for more complicated ones for the surgeon. Growth of healthcare infrastructure in India and China leads to increased access to the technology.
In September 2025, the Royal Free Hospital in London launched a robotic gynaecology surgery programme, expanding UK access to minimally invasive procedures for complex endometriosis and oncologic cases, establishing the institution as a regional centre of excellence.
Recent Developments in the Robotic-Assisted Gynecological Surgery Market
- In July 2025, Intuitive Surgical disclosed that global surgeries performed using the da Vinci robots have risen by about 17% when compared to the second quarter of 2024 due to higher uptake of the da Vinci 5 robots. In the second quarter of 2025, the company sold 395 da Vinci surgical robots globally, against 341 units in the same quarter last year, with sales of da Vinci 5 units at 180 as against 70 units sold during the corresponding quarter in 2024. As of June 30, 2025, the total number of installed da Vinci robots was 10,488 across the world, an increase of 14% from 9,203 units in June 2024.
- In March 2025, The 2nd Global Multi-specialty Robotic Surgery Conference was successfully organized by SS Innovations International at Gurugram, Delhi, where live surgeries were demonstrated in gynecology. The conference showcased the latest applications of robots in gynecological oncology and reproductive surgery, with participation from many international surgeons, which improved the skills of institutions through Asia-Pacific healthcare networks. This conference was an indication of the increasing use of robotic surgery techniques in India's hospitals and improving the skills of surgeons in gynecological pathologies.
- In March 2025, the Institute of Post Graduate Medical Education and Research (IPGMER), in Kolkata, was the first government hospital in Eastern India to offer its patients robotic surgery facilities. The adoption of robotic surgical systems at the facility increased the availability of minimally invasive surgical methods in India's public health system, where surgeons could teach future surgeons how to perform surgeries using robots while offering their patients advanced gynecological operations.
- In December 2025, Medtronic received FDA approval for their Hugo robot-assisted surgical system for urological procedures, with further approval planned in gynecology and general surgery. The approval was a critical competitive achievement, posing a serious threat to Intuitive Surgical, which held a monopoly in the market for two decades, with the introduction of an innovative multi-quadrant access system.
- In January 2026, J&J applied to receive FDA de novo clearance for its Ottava robotic system for soft tissue surgeries. Ottava is a sophisticated soft tissue robotic surgical platform offering haptic feedback and visualization capabilities in addition to the modular design of instruments aimed at complex gynecological surgeries. J&J’s application for de novo classification meant that the company was going to become a direct competitor to Intuitive and Medtronic in the robotic surgery market.
Robotic-Assisted Gynecological Surgery Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends
Drivers: Minimally invasive surgery preference shifts patient recovery expectations and institutional procedural volume distributions substantially.
An increasing desire by patients for less pain after operations, fast recoveries and scars have completely transformed the way that surgery is performed in gynaecology. Using a robot allows for complex minimally invasive operations such as hysterectomy, myomectomy and surgery of endometriosis to be done via smaller incisions. The trauma caused to the body is thus much less when using a robot than using traditional open surgery. Healthcare organizations which respond to patient demands will invest in robots to satisfy patients’ requests for more complex operations. Surgeons realize better ergonomic conditions of working, less tremor and more dexterous instruments usage while using a robot. Differentiation of an organization by means of developing its robot program improves competitive position and attracts patients who look for complex surgeries. Equivalency of reimbursement for robotic and open approaches in major markets eliminates any financial disadvantages from performing such a transition.
Restraints: Capital equipment costs and annual servicing obligations create significant financial barriers limiting adoption across resource-constrained healthcare settings globally.
Individual robotic systems exceed USD 2 million in acquisition cost, with annual maintenance contracts typically ranging from USD 150,000 to USD 200,000 annually. Standalone ambulatory surgical centres and specialty clinics frequently lack capital capacity for system acquisition and ongoing support. Smaller hospitals in emerging markets face budgetary constraints preventing robotic investment despite demand for minimally invasive procedures. Surgeon training requirements necessitate substantial time investment and ongoing competency maintenance, increasing institutional costs beyond equipment acquisition. Stringent regulatory approval pathways for new robotic platforms extend development timelines and delay market entry of innovative competitors. International regulatory variability creates complexity for manufacturers pursuing global market expansion. Equipment compatibility limitations restrict interoperability with existing surgical infrastructure. Supply chain vulnerabilities create delays in system delivery and spare parts availability, particularly in Asia-Pacific and Latin American markets. These barriers perpetuate market concentration among established players with substantial capital resources and global manufacturing networks.
Opportunities: Artificial intelligence integration into robotic systems enables autonomous task completion and real-time surgical optimisation creating differentiation within competitive markets.
New innovations in AI technology are helping to foster growth in robotic gynaecological surgery by providing better anatomical recognition, positioning of the instruments, tissue cutting, and real-time surgical guidance. The development of single-port and modular robotic platforms is driving the applications of robotic techniques in the treatment of endometriosis and adnexal surgery, whereas robotic systems designed especially for gynaecological oncology are offering premium growth opportunities in the market. Robotic procedures performed in ambulatory surgical centers are generating more demand outside the hospital environment. Market growth in India, China, and Brazil can be expected due to healthcare investments and surgeon training programs in these regions.
Challenges: Limited training infrastructure and surgeon availability hinder widespread adoption of robotic-assisted gynaecological procedures across healthcare systems.
Many organizations do not have a specialized program for training on robotic surgery and, therefore, force surgeons to engage in fellowships that take a lot of time and resources. The training of surgeons to be able to independently operate on robotic consoles requires 50-100 supervised operations and, therefore, causes workflow problems during the process of adoption. Conflicts between retaining the know-how of open surgical processes and training on robotic procedures make prioritization difficult. Some patients' reluctance to undergo treatment through robotics is another barrier to adoption in markets where there is less awareness of the technology. There are different reimbursement standards between the healthcare systems of different regions, which poses a challenge for those institutions considering adopting this new technology. Rapid innovations make the technology obsolete within a short period, making the adoption process difficult due to upgrade requirements. Getting regulatory approval for a new robot takes much time and limits the number of options.
Trends: Competitive market fragmentation accelerates as new entrants challenge Intuitive's monopoly through differentiated platform designs and specialised clinical applications.
Hugo clearance by Medtronic and Ottava submission by Johnson & Johnson stand as landmark events in the shift of market structure from monopoly to multi-competition. Smaller players like CMR Surgical and Distalmotion adopt niching strategy focusing on procedures such as gallbladder surgery and hernia repair. Single-port robot is being increasingly accepted due to increased familiarity of surgeons and proven equivalence to multi-port system. Modularity and reconfigurability of robot platforms appeal to the institutions that seek such qualities in other surgical specialities besides gynaecology. Haptic feedback is becoming necessary as the surgeons get a better feel during remote manipulation. AI enabled surgical modules have evolved from mere research to applications as they offer better standardisation of procedures. Cloud enabled collaborative platforms for surgery allow remote proctoring and global collaboration amongst the community of robotic surgeons. The number of procedures will increase with more training of surgeons.
Where Are the Biggest Opportunities in the Robotic-Assisted Gynecological Surgery Market?
- Expanding single-port robotic system adoption addresses patient preferences for minimal scarring and rapid recovery, targeting particularly younger reproductive-age women undergoing endometriosis and myomectomy procedures.
- Artificial intelligence integration into robotic platforms enables autonomous task assistance and real-time surgical guidance, creating competitive differentiation and enhanced surgeon confidence during complex anatomical dissection.
- Ambulatory surgical centre expansion for robotic gynaecological procedures reduces institutional capital requirements and creates growth in outpatient environments serving working-age women needing rapid return to daily function.
- Gynaecologic oncology robotics represents premium pricing opportunity as complex cancer procedures demand specialised platforms and surgeon expertise concentrated in academic centres and cancer networks.
- Emerging market penetration in India, China and Brazil capitalises on rising healthcare investment, increasing prevalence of gynaecological disorders and expanding surgeon training infrastructure in rapidly developing economies.
- Modular robotic platforms addressing multi-specialty utilisation reduce per-procedure costs and create value for hospitals operating diverse surgical departments seeking infrastructure consolidation and capital efficiency.
- Force feedback and haptic technology integration enhances surgeon sensation during remote operation, creating competitive advantage and premium system positioning among innovation-focused healthcare organisations.
- Digital health platform integration enabling cloud-based surgical collaboration, remote proctoring and inter-institutional case sharing accelerates training and knowledge dissemination across geographically dispersed surgeon networks.
- Fluorescence-guided surgical capabilities improve tissue identification during endometriosis and oncologic procedures, creating precision medicine positioning and potential for improved oncologic outcomes in gynaecologic cancers.
- Women's health centre specialisation provides dedicated institutional infrastructure for robotic gynaecological procedures, creating brand differentiation and patient attraction strategies within competitive healthcare markets.
Robotic-Assisted Gynecological Surgery Market Segmentation Analysis
Report Attributes | Details |
Market Size in 2025 | USD 2.85 Billion |
Market Size by 2035 | USD 11.15 Billion |
CAGR (2026-2035) | 14.6% |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Historical Data | 2022-2024 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook |
Key Segments | By Robotic System: Multi-Port Robotic Systems, Single-Port Robotic Systems, Modular Robotic Systems, Specialised Robotic Platforms By Procedure: Robotic Hysterectomy, Robotic Myomectomy, Robotic Endometriosis Surgery, Robotic Pelvic-Floor Surgery, Robotic Adnexal Surgery, Robotic Gynecologic Oncology, Other Procedures By Technology: Telerobotics, Single-Port Robotics, Modular Robotics, 3D Visualisation, AI-Assisted Surgery, Force Feedback & Haptics, Fluorescence-Guided Surgery, Surgical Navigation By Clinical Indication: Uterine Fibroids, Endometriosis, Pelvic Organ Prolapse, Gynecologic Cancers, Abnormal Uterine Bleeding, Adnexal Disorders, Other Conditions By End User: Hospitals, Academic Medical Centres, Ambulatory Surgical Centres, Specialty Gynecology Clinics, Cancer Centres, Women's Health Centres |
Regional Analysis/Coverage | North America (U.S, Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, rest of Asia Pacific), LAMEA (Latin America, Middle East, and Africa) |
Company Profiles | Intuitive Surgical, Medtronic, Johnson & Johnson, CMR Surgical, Distalmotion, Medicaroid, SS Innovations, MicroPort MedBot, KARL STORZ, Asensus Surgical, Moon Surgical, Meere Company, Ronovo Surgical, Edge Medical Robotics, Momentis Surgical |
Source: Kaiso Research and Consulting
Robotic-Assisted Gynecological Surgery Market Segment Analysis
- By Robotic System: Multi-Port Robotic Systems dominated the "Robotic-Assisted Gynecological Surgery Market" in 2025 with approximately 58% share; Single-Port Robotic Systems is the fastest-growing segment with a CAGR of approximately 19.2% from 2026 to 2035.
- By Procedure: Robotic Hysterectomy dominated the "Robotic-Assisted Gynecological Surgery Market" in 2025 with approximately 42% share; Robotic Endometriosis Surgery is the fastest-growing segment with a CAGR of approximately 16.8% from 2026 to 2035.
- By Technology: 3D Visualisation dominated the "Robotic-Assisted Gynecological Surgery Market" in 2025 with approximately 35% share; AI-Assisted Surgery is the fastest-growing segment with a CAGR of approximately 24.3% from 2026 to 2035.
- By Clinical Indication:Uterine Fibroids dominated the "Robotic-Assisted Gynecological Surgery Market" in 2025 with approximately 39% share; Gynecologic Cancers is the fastest-growing segment with a CAGR of approximately 17.5% from 2026 to 2035.
- By End User: Hospitals dominated the "Robotic-Assisted Gynecological Surgery Market" in 2025 with approximately 56% share; Ambulatory Surgical Centres is the fastest-growing segment with a CAGR of approximately 18.9% from 2026 to 2035.
Dominating Segments in the Robotic-Assisted Gynecological Surgery Market
By Robotic System: Multi-port platforms establish clinical reference standards across established surgical robotics programmes globally.
Multi-port robotic systems dominate the market through proven surgeon capabilities, clinical evidence, and broad acceptance in both academic medical centers and big hospital chains. Da Vinci Surgical Systems hold about 58% market share owing to their superior ergonomic capabilities, clinical performance, and training programs. Surgeons that perform complicated surgeries including gynecological oncology and pelvic floor reconstruction need multi-port technology because it allows better instrument triangulation and tissue visibility. Single-port robotic systems have the largest growth rate with an estimated CAGR of about 19.2%, entering the field of hysterectomies and adnexal surgery due to superior cosmetic results and faster recovery time among women of reproductive age. Modular systems and specialized systems take up about 12% market share each. The clinical evidence suggests that the safety profile is the same for different robotic systems, hence allowing market diversification depending on institutional needs and certain procedures. Based on the forecast, the single-port systems will have about 28% market share by 2035 while the multi-port systems will decrease their market share down to about 48%.
In Q2 2025, Intuitive Surgical installed 180 da Vinci 5 multi-port systems globally compared with 70 systems in the prior year, demonstrating sustained market preference for advanced multi-port platform capabilities across established surgical robotics programmes.
By Procedure: Robotic hysterectomy procedures dominate gynecological surgical volume through established clinical evidence and seamless integration within institutional operative schedules.
Robotic hysterectomy accounts for about 42% of robotic gynaecologic surgeries, involving benign cases such as uterine fibroids, adenomyosis, and abnormal uterine bleeding treatments. The familiarity with the procedure, relative simplicity in technique and the fast learning curve help surgeons perform well with regard to training in robotic surgery. The fast growing procedure category is robotic endometriosis surgery, which amounts to about 16.8% CAGR, due to surgeon's increasing expertise in dissections and patients' increasing knowledge about improved cosmesis and functional preservation compared to open surgery. About 22% of procedures involve pelvic floor surgery and adnexal procedures. Robotic gynecologic oncology is confined to academic institutions and cancer networks because of the necessity for specialized training. With the increasing experience and wider range of applications in addition to the traditional indications for the procedure, the variety of surgical procedures increases faster. Based on forecast analysis, robotic endometriosis surgery will account for about 23% of total procedure volume by 2035.
In September 2025, endometriosis patients at the Royal Free Hospital benefited from robotic-assisted dissection techniques enabling superior identification of disease implants and preservation of reproductive function compared to conventional laparoscopic approaches.
By Technology: Three-dimensional high-definition visualisation enables precise tissue identification and anatomical orientation during minimally invasive gynaecological procedures.
The 3D visualisation systems lead in adoption at approximately 35%, offering surgeons a better depth perception than 2D images. Improved visualisation helps to increase the success rate of endometriosis implants identification and decreases the amount of operative bleeding. AI-assisted surgery is the most rapidly developing technology at approximately 24.3% CAGR, where the new algorithms allow for performing tasks independently and give surgical guidance. Telerobotics allowing distant control of a robot by a surgeon over large distances is implemented in approximately 12% of robots. Force feedback and haptic technology are included into approximately 18% of systems, improving the feeling of a surgeon during the remote control. Fluorescence-guided surgery and surgical navigation constitute approximately 8% technology adoption rate. The pace of technologies' incorporation increases as the systems grow more mature and competitive pressures arise. AI-assisted surgery adoption forecast model suggests that it will reach approximately 38% adoption rate in 2035.
In December 2025, Medtronic's Hugo system clearance incorporated advanced 3D visualisation and preliminary AI-assisted capabilities, positioning emerging technology integration as competitive requirement for market success.
By Clinical Indication: Uterine fibroids dominate clinical indications for robotic-assisted gynaecological surgery through high prevalence rates and well-established minimally invasive management paradigms.
Uterine fibroids comprise approximately 39% of all robotic gynaecologic surgeries, owing to prevalence of 70-80% amongst women of age 50 years. Robotic myomectomy allows resection of complex multifibroids while retaining the functionality of the uterus, being ideal for women in their reproductive age. The second most common indication is endometriosis, comprising approximately 19% of cases, owing to disease prevalence of approximately 10% among reproductive aged women. Robot-assisted endometriosis surgery is growing the fastest at an annual growth rate of 17.5%, due to advancement in surgical technique, increased awareness and expertise of surgeons. Gynecologic cancers comprise approximately 21% of all procedures, which are mainly performed at academic medical centers and cancer networks due to specific training needs. Abnormal uterine bleeding, pelvic organ prolapse and adnexal conditions collectively comprise about 12% of all indications. Increased clinical evidence and outcomes research accelerate the uptake of robotics across different indications. Projections anticipate gynecologic oncology surgeries to account for approximately 28% of all surgeries by 2035.
In March 2025, IPGMER's robotic programme expansion in Kolkata enhanced institutional capacity for complex endometriosis and fibroid management procedures across government-funded healthcare systems in eastern India.
By End User: Hospital surgical departments dominate robotic-assisted gynaecological surgery adoption through established capital resources, dedicated operating theatres and integrated training infrastructure.
Hospitals constitute about 56% of robotic systems installation, delivering centralised robotic surgery capabilities for various gynaecological specialties within integrated healthcare settings. Academic medical centers host around 24% of robotic systems, fostering innovation, surgeon training and information exchange. Ambulatory surgical centers constitute the fastest growing end-users segment at about 18.9% CAGR, making robotic capabilities available for outpatient surgeries such as hysterectomy, myomectomy, and endometriosis. Specialty gynaecology clinics and cancer centers together make up about 12% of installed robotic systems. Women’s health centers present as emerging market in retail and integrated healthcare sectors. The end-user diversification trend gains momentum due to procedure standardization and growth in the body of evidence on outpatient surgeries. Analysis of forecasts shows that ambulatory surgical centers will adopt robotic systems at the rate of about 32% of total systems by 2035.
In 2025, ambulatory surgical centres expanded robotic hysterectomy and myomectomy programmes, reducing procedural costs by approximately 25-35% compared to hospital-based operations whilst maintaining clinical safety and patient satisfaction.
Regional Insights in the Robotic-Assisted Gynecological Surgery Market
Regional Analysis
Region | Major Country | Share within Region, 2025 (%) |
North America | United States | 82 |
Europe | Germany | 28 |
Asia Pacific | China | 35 |
Latin America | Brazil | 42 |
North America: Established surgical infrastructure and concentrated payer reimbursement accelerate robotic platform adoption across progressive healthcare systems.
North America constitutes about 48% market share of the global robotic-assisted gynaecological surgery. Such a strong market growth rate is attributed to the region's developed healthcare infrastructure, considerable capital investment ability, and reimbursement parity between robotic and open surgeries. Robotic programs in healthcare organizations in North America have been invested in to cater for patient needs for minimally invasive options and also lure high-volume surgeons. North America's fastest growing market is led mainly by the USA growth and shows about 14.8% CAGR. Innovator hospitals are concentrated in North America which gives access to emerging technology such as artificial intelligence and haptic feedback. Regulators' frameworks favor quick adoption of the cleared technologies, thereby ensuring constant platform enhancements. Training facilities have been found to be limited in large medical centers, but surgeon competency is increasing at various types of institutions. R&D infrastructure investments in North America make it a leader in technological innovations. Reimbursement policies and health care coverages favor robotic procedures in almost all major payers.
In 2025, major North American hospital systems including Mayo Clinic and Stanford Health expanded robotic gynaecological surgery programmes, positioning minimally invasive approaches as standard of care for complex fibroid and endometriosis management.
USA: Advanced healthcare infrastructure and established robotic surgical ecosystems position the United States as global market leader and innovation catalyst.
The robotic assisted gynaecological surgery market in the USA will have a value of USD 1.36 billion in 2025 and reach USD 5.35 billion by 2035 at a CAGR of 14.8% between 2026 to 2035. The USA represents around 82% share of the North America market due to adoption of the technology, extensive surgeon training and insurance reimbursements. Large academic teaching hospitals in Boston, New York, California, and Texas are adding more robotic surgery programs, leading to increased volume of procedures across health care networks. Innovation is driven through clinical trials of AI-assisted and force feedback surgery within academic medical centers. Reimbursement by Medicare and insurance companies reduces financial barriers in adoption. Ambulatory surgery centers increase volumes of procedures with adoption of robotic technology. FDA approval and authorization enable commercialization and increase competition among technology manufacturers like Intuitive, Medtronic, and Johnson & Johnson. Aging population, prevalence of gynaecological diseases and preference for minimally invasive surgery will drive market growth during the forecast period.
In Q3 2025, Intuitive Surgical reported 19% growth in da Vinci procedure volume across all surgical specialties in the United States, with gynaecological procedures representing the largest single-specialty growth driver.
Europe: Regulatory harmonisation and public healthcare system evolution enable gradual robotic adoption across diverse institutional environments.
Europe constitutes about 22% of the global robotic-assisted gynaecological surgery market and will exhibit a CAGR of 13.2% owing to increasing opportunities for training surgeons and higher insurance coverage. Germany dominates the regional market with a market share of approximately 28%, thanks to academic medical centers and investments in private health care. UK has been developing more robotic surgery programs in hospitals such as Royal Free Hospital and NHS teaching hospitals. France and Italy have also seen an increase in robotic surgery use with the help of teaching hospitals and growing demand for minimally invasive techniques. However, the inconsistency in the reimbursement policies makes the adoption rates uneven, with public health care lagging behind private and academic organizations. EU medical device regulations make the process of gaining approval consistent, helping with the commercialization of the platform in the member states. Fellowships and specialized training centers boost surgical skills. Although there are budget restrictions and pressure on costs, improvement in clinical and economic value evidence will help advance insurance coverage. Europe continues to be a promising market for growth and attracts investments from robotic surgery vendors.
In September 2025, the Royal Free Hospital launched a dedicated robotic gynaecology surgery programme, positioning the institution as a European centre of excellence and expanding access to minimally invasive procedures across United Kingdom patients.
Asia-Pacific: Rapid healthcare system modernisation and rising surgical volumes position Asia-Pacific as highest-growth global region for robotic-assisted gynaecological surgery.
Asia-Pacific contributes around 18% of the global market and is estimated to experience a CAGR of about 17%. Growth will be driven by increasing healthcare spending as well as increased incidence of gynaecological diseases. China is a frontrunner in adopting the technology with an estimated 35% market share owing to development of healthcare and investment in robotic surgery technology in teaching institutions as well as private hospitals. Adoption in India has been fast due to increasing institutional investments and surgeon training programs. Healthcare facilities are increasing minimally invasive procedures to prevent post-procedure complications. International and domestic fellowships enhance surgical skills for wider adoption of the technology. Capital investments and poor infrastructure are factors that have hindered adoption in certain regions. Changes in reimbursement policies and growing clinical evidence will aid access to technology. Technology transfer agreements will make use of advanced platforms easier at affordable costs. Higher healthcare expenditure and incidence of endometriosis and uterine fibroids will fuel adoption. Asia-Pacific provides a good opportunity for growth as the healthcare infrastructure improves and more procedures are performed using the technology.
In March 2025, SS Innovations hosted the 2nd Global Multi-Specialty Robotic Surgery Conference in Delhi, attracting international surgeons and demonstrating accelerating Asia-Pacific leadership in robotic gynaecological innovation and clinical applications.
Japan: Ageing population and established healthcare infrastructure create specialised opportunity within Asia-Pacific for premium robotic systems and innovative applications.
Japan is one of the countries in the Asia-Pacific region that has a distinctive place in the healthcare system due to the possession of 22% of regional market share with mature healthcare system attributes. Japan's demographic age structure makes the country face growing numbers of surgeries due to conditions such as uterine fibroids and pelvic organ prolapse in robotic settings. In Japan, medical device companies like Medicaroid produce competitive robotic systems aimed at both regional and global markets. Health care system priorities of precision medicine and minimal invasiveness contribute to robotic procedures being performed in teaching hospitals and advanced private institutions. Surgeon training programs meet international standards because Japanese gynecological surgeons train for fellowships in various parts of the world and create robotic training programs upon their return. Universal health insurance systems provide the reimbursement of robotic procedures at an affordable price, making possible widespread adoption of such procedures in institutions. Japan exhibits about 14.3% CAGR in the Asia-Pacific region due to its mature market attributes and procedure expansion beyond traditional procedures. Innovative investments by Japanese electronics and medical device companies make Japan a potential robotics innovator in the global setting.
In 2024, Medicaroid expanded robotic surgical system sales across Japanese healthcare systems, with gynaecological indications representing an increasing proportion of institutional adoption.
LAMEA: Healthcare system development and rising disease prevalence create emerging opportunity within resource-constrained settings for accessible robotic-assisted gynaecological surgery.
LAMEA accounts for about 12% of total market share growing at a robust CAGR of 12.8%, propelled by healthcare reforms and increase in surgical demand. Brazil is the leading adopter of robotic technology with about 42% of the regional market share, attributed to concentrated investments in teaching hospitals and the private healthcare sector. Robotic programs are being accelerated in Argentina and Mexico with respect to the leading academic medical centers. Middle Eastern nations like Saudi Arabia and United Arab Emirates invest in modernizing their healthcare infrastructure for robotic systems acquisition. Healthcare system of Africa is concentrated in the urban centers owing to limitations of capital but with increased investments in flagships; an adoption opportunity emerges. Reimbursement strategies are under-developed in the LAMEA region, making adoption challenging despite clinical need. Training infrastructure is also concentrated in major academic centers with surgeons preferring international fellowship training programs. Transfer of technology through partnership allows for acquiring robotic systems at relatively lower costs compared to acquisition. Increase in patient demand for minimally invasive surgery is fueled by increase in healthcare awareness and decrease in patient traveling abroad.
In 2025, major Brazilian healthcare systems expanded robotic gynaecological surgery programmes, introducing minimally invasive approaches for complex fibroid and endometriosis management within private and academic institutional settings.
How Can Stakeholders Benefit from the Robotic-Assisted Gynecological Surgery Market Report?
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.

